🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

💭Whether or not you believe in adverse radiation effect (ARE) after pre-op SRS, why deliver high doses to brain lesions when you can get away with less? This group found no difference in 2-year ✅cavity local recurrence ✅ARE ✅nodular leptomeningeal disease ✅OS between

Advances, an ASTRO Journal Great work from Roshan, definitely the future. I’m a strong believer in fractionated preop more data to come!!

📌Standard Dose Versus Reduced Dose Single Fraction Preoperative Radiosurgery for Resected Brain Metastases: A PROPS-BM International Multicenter Cohort Study advancesradonc.org/article/S2452-… 👉🏻 307 patients with 307 index lesions ≤ 4 cm in maximum dimension treated with single

This truly collaborative study embodies what we strive for at Advances in Radiation Oncology... innovation! Want to add the newest & best to your skin RT practice? ⁉️Ever heard of Rhenium-skin cancer therapy? It is a non-invasive, epidermal radionuclide treatment for

Want a comprehensive meta-analysis of 15 metastasis-directed therapy (MDT) trials? 🔖Bookmark this post! This analysis found that MDT ✅significantly improved progression-free survival for all ✅benefited non-mutated or EGFR-mutated 🫁NSCLC & 👨‍🦳prostate cancer the most (not

Just a reminder to get those RT for benign disease projects going!

Have questions about our call for benign disease manuscripts?! Message us!

☢️for benign dx is a 🔥 topic in #radonc: RT (20-30 Gy) for orbital inflammatory dx (Graves, IgG4, etc) associated with: -🔽steroid use: complete (56%), partial (33%) taper -🔽 👁️symptoms: diplopia, ptosis - <5% late side effects (dry 👁️, opacity) tinyurl.com/4bfxazbf

PSMA radioligand therapy (PSMA-RLT) has a 📈survival benefit in metastatic castration resistant prostate cancer. But can we do a better job of choosing who RLT can benefit most❓🤔 👀Check out this case series that uses TRAQinformIQ, an automated image analysis tool, to

In NSCLC, how does length of esophagus receiving ☢️impact patient-reported dysphagia? -Every 0.5cm 🔼 in 60 Gy to partial esoph circumference > 🔼 patient-reported dysphagia by 9% -Every 0.5cm 🔼 in 60+ Gy to full esoph circumference > 🔼 patient-reported dysphagia by 11%

We are accepting articles for this special call now!

❗️Out now in Advances❗️ Prospective outcomes after proton re☢️(median 44.6 Gy) for pts w/ recurrent gliomas: 🔘 mOS 11.2mo - 🔼 w/ oligo histology, >60 mo from prior ☢️ 🔘 Acute G3 toxicity 8% -🔼 w/ poor PS (ECOG 2-3) 🔘 Late G1☢️necrosis: 19% tinyurl.com/38zk4aun

Teaching Case: What are the outcomes after SBRT for urothelial ca of a transplanted kidney? After 13 mo, ☢️(40/5) to transplanted kidney associated w: 🔘❌ early/late adverse events 🔘✅ local control 🔘✅ stable eGFR RT planning + constraints reviewed:

Thrilled to share our impact factor is rising and the highest it’s been since inception! Special thanks to our editors, editorial staff, and most of all, our readership and contributors to the journal!!! #ASTRO

❗️OUT NOW - Dosi predictors of toxicity on PROMETHEUS study ❗️ In ♂️ w/ HR Pca receiving ☢️(46/23 + 19-20/2 SBRT boost), G2+ GU tox assoc w/ 🔘 Prior TURP 🔘 Prostatic urethra length 🔘 Urethra PRV volume 🔘 Bladder D10cc and D15cc #pcsm #radonc - tinyurl.com/3efsntx5

A prior study showed that male ♂️academic #radoncs are 3x times more likely to treat genitourinary (GU) maligancies than their female ♀️counterparts, and ♀️ #radoncs are more than twice as likely to treat gynecologic (GYN) malignancies than ♂️. With that in mind, what do female

❗️Out now: tinyurl.com/ycxku7pr❗️ In this Ph II trial (n=26), addition of IO (before, during, after) to definitive chemo☢️for pts w/ LA p16+ OPCs (cT4/3, matted LN, cENE) had: 🔘 2yr PFS: 65% (vs 68% historic control) 🔘 G3+ acute dysphagia: 54% 🔘 Incomplete IO course: 68%